Obesity is a serious condition associated with accumulation of fat inside body that also predisposes the subject to other complicated disorders. Inhibition of pancreatic lipase enzyme that regulates absorption of lipids in gastrointestinal tract is an effective strategy to counter obesity and high levels of lipids in blood. Orlistat acts via this mechanism and hence was selected as the standard drug in this study. Phthalimide moiety is capable of being employed to generate new anti-obesity drugs and thus three new derivatives were synthesized which also possess partial resemblance to the structure of orlistat. Acute toxicity study was performed and each derivative was administered in the dose of 100 mg/kg orally. Orlistat was administered at the dose of 250 mg/kg orally. Each derivative produced significant reduction in bodyweight of animals when compared to negative control group animals. Triton produced elevation in serum cholesterol and triglycerides levels in the animals of positive control group at the dose of 400 mg/kg i.p. At the same time, orlistat and other synthesized derivatives prevented rise in serum cholesterol and triglycerides levels in animals of respective groups at the dose of 250 mg/kg and 100 mg/kg respectively when given orally. It can be concluded that these new derivatives possess considerable action as anti-obesity and lipid lowering agents. Further experiments are undergoing to elucidate their exact mechanism in obesity and hyperlipidaemia.
Loading....